Unique characteristics of histone deacetylase inhibitors in reactivation of latent HIV-1 in Bcl-2-transduced primary resting CD4+ Tcells

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 1, 2014, Pages 28-33

  Shan, Liang ^a   Xing, Sifei ^a   Yang, Hung Chih ^b   Zhang, Hao ^c   Margolick, Joseph B ^c   Siliciano, Robert F ^a,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Cytotoxicity; Latent reservoir; Vorinostat

Indexed keywords

GREEN FLUORESCENT PROTEIN; HISTONE DEACETYLASE INHIBITOR; PROTEIN BCL 2;

ARTICLE; CD4+ T LYMPHOCYTE; DRUG EFFICACY; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE SUBPOPULATION; MEMORY T LYMPHOCYTE; PROTEIN EXPRESSION; SHORT COURSE THERAPY; SIGNAL TRANSDUCTION; VIRUS LATENCY; VIRUS REACTIVATION;

CYTOTOXICITY; LATENT RESERVOIR; VORINOSTAT;

CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; HISTONE DEACETYLASE INHIBITORS; HIV-1; HUMANS; STAINING AND LABELING; VIRUS ACTIVATION; VIRUS LATENCY; VIRUS REPLICATION;

EID: 84890420088     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt338     Document Type: Article

References (20)

1. Finzi D, Hermankova M, Pierson T et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278: 1295-300.
2. Wong JK, Hezareh M, Gunthard HF et al. Recovery of replicationcompetent HIV despite prolonged suppression of plasma viremia. Science 1997; 278: 1291-5.
3. Chun TW, Stuyver L, Mizell SB et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997; 94: 13193-7.
4. Margolis DM. Histone deacetylase inhibitors and HIV latency. Curr Opin HIVAIDS 2011; 6: 25-9.
5. Mbonye U, Karn J. Control of HIV latency by epigenetic and non-epigenetic mechanisms. Curr HIV Res 2011; 9: 554-67.
6. Contreras X, Schweneker M, Chen CS et al. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem 2009; 284: 6782-9.
7. Ylisastigui L, Archin NM, Lehrman G et al. Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS 2004; 18: 1101-8.
8. Reuse S, Calao M, Kabeya K et al. Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One 2009; 4: e6093.
9. Savarino A, Mai A, Norelli S et al. 'Shock and kill' effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. Retrovirology 2009; 6: 52.
10. Burnett JC, Lim KI, CalafiA et al. Combinatorial latency reactivation for HIV-1 subtypes and variants. J Virol 2010; 84: 5958-74.
11. Huber K, Doyon G, Plaks J et al. Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells. J Biol Chem 2011; 286: 22211-8.
12. Matalon S, Rasmussen TA, Dinarello CA. Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir. Mol Med 2011; 17: 466-72.
13. Yang HC, Xing S, Shan L et al. Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin Invest 2009; 119: 3473-86.
14. Archin NM, Liberty AL, Kashuba AD et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012; 487: 482-5.
15. Coull JJ, Romerio F, Sun JM et al. The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J Virol 2000; 74: 6790-9.
16. Williams SA, Chen LF, Kwon H et al. NF-kB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J 2006; 25: 139-49.
17. Keedy KS, Archin NM, Gates AT et al. A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. J Virol 2009; 83: 4749-56.
18. Bradner JE, West N, GrachanML et al. Chemical phylogenetics of histone deacetylases. Nat Chem Biol 2010; 6: 238-43.
19. Shan L, Deng K, ShroffNS et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012; 36: 491-501.
20. Archin NM, Keedy KS, Espeseth A et al. Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. AIDS 2009; 23: 1799